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ABSTRACT
Background: Japanese cedar pollinosis (JCPsis) affects nearly one in six Japanese. Oral administration of
Bifidobacterium longum BB536 has been shown to be effective in relieving JCPsis symptoms during the pollen
season.
Methods: This double- two-way crossover study was designed to evaluate the efficacy of BB536 on reducing
symptoms in JCPsis patients exposed to Japanese cedar pollen (JCP) in an environmental exposure unit
(EEU) outside of the normal JCP season. After a 1-week run-in period, subjects (n = 24) were randomly allo-
cated to receive BB536 powder (approximately 5 × 1010) or placebo twice a day for 4 weeks. After a 2-week
washout period, subjects were crossed over to another 4 weeks of intake. At the end of each intake period,
subjects received controlled JCP exposure for 4 hours in the EEU. Symptoms were self-rated 30 minutes be-
fore and every 30 minutes during the exposures. From the first day of exposure through the next 5 successive
days, participants self-rated their delayed symptoms and medication uses. Blood samples were taken before
the exposures. The mean JCP levels for exposures were 6500 to 7000 grainsm3 air.
Results: In comparison with placebo, BB536 intake significantly reduced the ocular symptom scores during
JCP exposures. Evaluating delayed symptoms after exposures indicated that scores for disruption of normal
activities were significantly lower in the BB536 group compared with the placebo group. Prevalence of medica-
tion use was markedly reduced by BB536 intake.
Conclusions: These results suggest the potential beneficial effect of BB536 in relieving symptoms of JCP al-
lergy
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INTRODUCTION
Allergic rhinitis is a common disorder affecting a
large percentage of the population, with estimates of
the prevalence ranging from 9 to as high as 42%.1,2
This disorder can be classified as seasonal or peren-
nial depending on whether symptoms are manifested
at defined yearly intervals or throughout the year, re-
spectively. Japanese cedar pollinosis (JCPsis) is an
immunoglobulin E (IgE)-mediated type I allergy
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caused by exposure to Japanese cedar (Cryptomeria
japonica) pollen (JCP) that is normally released from
early February until the end of April. Over recent dec-
ades there has been an increasing prevalence of this
allergy and this public health issue now affects >16%
of the Japanese population.3 Drugs such as antihista-
mines and local steroids are commonly used to re-
lieve symptoms, but some of these therapies can
cause adverse effects such as sleepiness and thirst.
As of yet, there is no complete recovery measure-
ment known for this disorder, although presently,
allergen-specific immunotherapy is considered to be
the most promising.4
Numerous studies have reported that the intake of
probiotics such as lactobacilli and bifidobacteria is as-
sociated with the prevention of several allergic dis-
eases,5-10 but for other strains conflicting results have
been reported.11 We previously reported that the in-
take of Bifidobacterium longum BB536 was potentially
effective in relieving JCPsis symptoms and modulat-
ing the Th1Th2 balance. In 2004, we performed a
human trial to investigate the effects of yogurt supple-
mented with BB536 in the treatment of JCPsis during
the pollen season. We found that some of the subjec-
tive symptoms were alleviated following BB536 in-
take, while decreased interferon (IFN)-γ levels were
particularly suppressed at the early stage of pollen
season.12 The effect of BB536 in the treatment of
JCPsis was confirmed during the 2005 pollen season
by using lyophilized powders of BB536. We found
that BB536 intake alleviated subjective symptoms
leading to an increase in the number of JCPsis sub-
jects who did not need to use their prescribed pollino-
sis medicines during the pollen season.13 BB536 was
found to significantly suppress the increase of plasma
thymus- and activation-regulated chemokine (TARC),
a Th2 marker, during the pollen season.13 These re-
sults suggested that BB536 was effective in relieving
JCPsis symptoms, with the mechanism most likely
due to the modulation of the immune response.
The present study was a double-blind two-way
crossover study designed to be performed out of the
JCP season and to assess the efficacy of BB536 intake
on the reduction of symptoms after JCP exposure in
an environmental exposure unit (EEU) in JCPsis pa-
tients. The EEU concept has been developed to over-
come the problems associated with field-based stud-
ies. The EEU used in this particular study is located
in Wakayama, Japan. The design of the unit allows for
control of the temperature and humidity and enables
simultaneous allergy challenge in up to 28 subjects
under controlled and reproducible conditions for sev-
eral hours at a time. In studies of the efficacy of anti-
histamine drugs against JCP challenge, the
Wakayama EEU has been validated to provide repro-
ducible and consistent results.14,15 EEUs located in
Canada, Austria and other countries have also been
demonstrated to be useful in the evaluation of the on-
set, efficacy and duration of medicines used for treat-
ing different kinds of seasonal allergies.16-20 However,
to the best of our knowledge, there have been no
prior reports on the application of an EEU in the
evaluation of the efficacy of probiotics in the treat-
ment of allergy diseases.
METHODS
PARTICIPANTS
For this intervention, a total of 24 adult volunteers (10
men, 14 women) with a clinical history of JCPsis were
recruited from the area around Wakayama Prefec-
ture. Participants were screened on the basis of a >2-
year clinical history of JCPsis, the presence of serum
JCP-specific IgE and the presence of relatively severe
symptoms during the last cedar pollen season as
evaluated in accordance with the Practical Guidelines
for the Management of Allergic Rhinitis in Japan (PG-
MARJ) 2005. None of the subjects had been taking
any rhinitis medication prior to the start of this inter-
vention.
All participants provided written informed consent.
All study protocols were approved and controlled by
the Local Ethics Committee of the NPO (non-profit
organization) Japan Health Promotion Supporting
Network, Wakayama, Japan, and the Local Ethics
Committee of Morinaga Milk Industry Co., Ltd., To-
kyo, Japan.
SAMPLE INTAKE AND PARTICIPANT MONITOR-
ING
The study was designed as a double-blind two-way
crossover study. After a 1-week run-in period, sub-
jects (n = 24) were randomized into 2 groups (group
A and group B) and allocated to receive either a
freeze-dried powder of BB536 (approximately 5 ×
1010) or a placebo powder (only internal matrix,
which consisted mainly of dextrin) twice a day for 4
weeks. After a 2-week washout period, volunteers
were crossed over to another 4 weeks of intake (Fig.
1). BB536 and placebo powders looked and tasted
identical. To improve the survivability of probiotics in
delivery to the intestinal tract, participants were in-
structed to suspend the powder in 100 ml of ultra-
high temperature pasteurized milk prior to ingestion
of the samples. At the end of each interventional pe-
riod, each subject received controlled JCP exposure
(4 hours) in the EEU. The mean pollen levels were
6500 to 7000 grainsm3 air, which were approxi-
mately 2 times higher than the heaviest dispersion
documented during the 2005 pollen season. Partici-
pants were instructed to complete a questionnaire on
compliance, medication and health conditions
throughout the intervention. For the JCP exposure,
all participants arrived at the site in the morning, and
prior to pollen exposure, physical examinations and
blood draws were performed. Symptoms were self-
rated 30 minutes before exposure and every 30 min-
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Fig. 1 Study protocol.
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utes during the exposure. Nasal blockage, eye itch-
ing, watery eyes, throat symptoms (such as a
scratchy or sore throat) and disruption of normal ac-
tivities (for example, the impact of the symptoms on
reading a book or watching TV in the EEU) were
evaluated using a 10-cm visual analogue scale (VAS;
maximum score, 10). Counts of the episodes of
sneezing and nose blowing (rhinorrhea) were re-
corded. Scores for eye itching and watery eyes were
summed for the measure of ocular symptoms for
each subject. Since the outcomes of episode counts of
sneezing and nose blowing were well balanced with
those observed for the VAS scores of nasal blockage,
they were directly summed to provide the measure of
nasal symptoms for each subject.
After exposure, each participant underwent a sec-
ond physical examination and nasal lavage with ap-
proximately 100 ml of phosphate-buffered saline used
to remove pollen from the nasal cavity. For delayed
symptoms, eye drops (histamine release inhibitors),
local nasal sprays (focal administration of steroids)
and oral medications (second generation antihista-
mines) were prescribed. Participants were instructed
to record delayed subjective symptoms and medica-
tions that were used starting from the first day of ex-
posure and continuing for 5 successive days after ex-
posures. Participants were allowed to try self-care
measures such as the use of prescribed eye drops, lo-
cal nasal sprays or oral medication when necessary.
All participants were requested to record use of these
items on a daily basis. Nasal blockage, eye itching,
watery eyes, throat symptoms, and disruption of nor-
mal activities (for example, the impact of the symp-
toms on work, study, housework, sleep, or outdoor
activities) were evaluated daily using a 10-cm visual
analogue scale (VAS; maximum score, 10). Counts of
episodes of sneezing and nose blowing (rhinorrhea)
were recorded daily. Daily scores for eye itching and
watery eyes were summed for the measure of ocular
symptoms for each subject. The daily counts of epi-
sodes of sneezing and nose blowing after exposures
were transformed to ordinal scores from 0 to 4 as fol-
lows; 0, none; 1, 1―5 episodes; 2, 6―10 episodes; 3,
11―20 episodes; and 4, >21 episodes in accordance
with the PG-MARJ 2005. The outcomes of ordinal
scores of sneezing and nose blowing were well bal-
anced with those observed for daily VAS scores of na-
sal blockage, and therefore they were summed as a
measure of nasal symptoms for each subject.
BLOOD SAMPLING
Physical examinations and blood samplings were per-
formed during the screening, and after each of the
sample intake periods. Blood samples were drawn
from an antecubital vein after overnight fasting. Se-
rum total IgE antibodies and JPC-specific IgE anti-
bodies were analyzed using the UniCap system (Di-
agnostic, Sweden).
STATISTICAL ANALYSIS
The basic data are presented as geomeans with 95%
Confidence intervals (CI). To compare scores over
the entire phase, area-under-the curves (AUCs) dur-
ing and after exposures were then calculated based
Xiao J et al.
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Fig. 2 Mean scores for subjective symptoms before and during polen exposure in the environ
mental exposure unit for the BB536 group (closed squares) and placebo group (open circles). (A) 
Nasal symptoms; (B) Ocular symptoms; (C) Throat symptoms; (D) Disruption of normal activities. 
Data are expressed as geomeans. † ,p＜0.1; ＊p＜0.05, diference between groups.
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Table 1 Subject characteristics
Group B (BB536→placebo)Group A (placebo → BB536)
1110Number of participants†
37.6 ± 7.541.0 ± 8.0Age (years)
(25―50)(27―56)(range, years)
n＝5n＝4MaleGender
n＝6n＝6Female
148.1 (95.7―447.0)113.5 (67.6―417.3)IU/mlTotal IgE‡
 21.2 (18.0―48.5)12.9 (10.2―26.3)UA/mlJCP-specific IgE2)
†Means ± SD　‡Geometric means (95% confidence intervals)
on subjective symptom scores for each subject. Good-
ness of fit test for the normality of the data revealed
that the symptom scores and AUCs did not follow a
normal distribution. Therefore, logarithmic transfor-
mation of the data was used to alleviate the deviation
from the normality. Since this study is two-way cross-
over design, firstly, the presence of a treatment-by-
period interaction was checked by analysis of vari-
ance methods including treatment, period and
treatment-by-period effect. Because the interaction
was not identified in this study for each variable, the
Wilcoxon signed rank test was performed to compare
BB536 efficacy with placebo. Medication scores were
analyzed similarly as symptom scores. Furthermore,
prevalence of medication use between the BB536 and
the placebo groups were compared using a chi-
square test or Fisher’s exact test. All statistical analy-
ses were performed using SAS statistical software
version 9.1.3 (SAS Institute, NC, USA). Values of p <
0.05 were considered statistically significant.
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Table 2 AUC analysis of symptom scores
p value
Scores in sum
BB536 groupPlacebo group
Total study group, n＝21
Symptoms during exposure
10.58 (5.76―19.46)11.80 (6.55―21.25)Nasal symptoms
0.0334.40 (2.70―7.18) 6.85 (4.20―11.18)Ocular symptoms
2.89 (1.85―4.51)2.08 (1.43―3.03)Throat symptoms
2.30 (1.44―3.67)2.23 (1.45―3.45)Disruption of daily routines
Symptoms post exposure
 9.39 (6.62―13.72)10.09 (7.08―14.39)Nasal symptoms
2.48 (1.64―3.76)2.81 (1.96―4.03)Ocular symptoms
1.79 (1.31―2.44)2.07 (1.48―2.89)Throat symptoms
0.0111.52 (1.15―2.00)2.03 (1.45―2.85)Disruption of daily routines
0.0931.17 (1.03―1.40)1.39 (1.07―3.07)Oral medicines
1.31 (0.97―2.07)1.44 (0.82―3.42)Nasal sprays
0.0471.20 (0.99―1.98)1.48 (0.99―3.20)Eye drops
0.0411.79 (1.20―2.65)2.27 (1.34―3.83)Total medications†
Values are expressed as geomeans (95% CIs).
†Sum of medication scores for oral medicines, nasal sprays and eye drops.
RESULTS
BASELINE CHARACTERISTICS OF PARTICI-
PANTS AND CONTINUED PARTICIPATION
Among the 24 subjects, one dropped out due to fail-
ure to undergo the second pollen exposure. Two sub-
jects (one in group A and one in group B) had colds
during the second exposure test and had extremely
high baseline symptom scores prior to the exposures.
Therefore, these two subjects were excluded from
the analysis of symptoms scores during and after ex-
posures. Baseline characteristics of the other 21 sub-
jects are shown in Table 1. The characteristics were
similar between the placebo and BB536 groups (Ta-
ble 1).
SYMPTOM SCORES DURING POLLEN EXPO-
SURE
Figure 2 shows mean scores for subjective symptoms
in each group. The baseline scores recorded 30 min-
utes before exposures were similar between the pla-
cebo and the BB536 groups for scores of nasal symp-
toms, ocular symptoms and disruption of normal ac-
tivities; however, slightly higher baseline scores were
found for throat symptoms in the placebo group com-
pared with the BB536 group (p = 0.114). Nasal symp-
tom scores increased rapidly, but other symptom
scores (ocular symptoms, throat symptoms and dis-
ruption of normal activities) increased gradually upon
exposure to pollens. No significant difference was ob-
served for the scores of nasal symptoms and disrup-
tion of normal activities; however, significantly lower
scores were found for ocular symptoms starting from
30 minutes after exposure to the pollens. There was
also no difference in the scores for each of the nasal
symptoms of sneezing, nose blowing and nasal block-
age between the two groups, but both of the scores of
eye itching and watery eyes were reduced in the BB
536 group (data not shown). Owing to the difference
of the baseline, a significant difference was found on
the throat symptom scores that were rated from 30 to
60 minutes. AUC analysis indicated a significant dif-
ference for the ocular symptom scores (p = 0.033),
but there was no difference found for the other symp-
toms (Table 2).
DELAYED SYMPTOMANDMEDICATION SCORES
AFTER POLLEN EXPOSURE
Remarkable delayed symptoms were observed begin-
ning with the first day of exposures and continued
through the next day (Fig. 3). No marked differences
were apparent in the nasal and ocular symptom
scores between the placebo and BB536 groups.
There was no difference in the scores for each of the
nasal or ocular symptoms between groups (data not
shown). Throat symptom scores tended to be lower
on the day after the exposures, and scores for disrup-
tion of normal activities tended to be lower on the two
days following exposure in the BB536 group com-
pared with the placebo. AUC analysis indicated a sig-
nificant difference (p = 0.011) for the scores of disrup-
tion of normal activities between the two groups, but
there was no difference for the other symptoms (Ta-
ble 2).
Medication use for relieving symptoms was ob-
served in some subjects, particularly on both the first
Xiao J et al.
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Fig. 3 Mean scores for subjective symptoms and medications after polen exposure in the envi
ronmental exposure unit for the BB536 group (closed squares) and placebo group (open circles). 
(A) Nasal symptoms; (B) Ocular symptoms; (C) Throat symptoms; (D) Disruption of normal 
activities. (E) Oral medicines; (F) Nasal sprays; (G) Eye drops; (H) Total medications. Data are 
expressed as geomeans. Total mediations are the sum of scores for oral medicines, nasal 
sprays and eye drops. † ,p＜0.1; ＊p＜0.05, diference between groups.
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Table 3 Prevalence of medication used post exposures
Numbers of subjects
Sumday 5day 4day 3day 2day 1day 0
Total study group, n＝21
18111249PlaceboOral medicines
 7＊000025BB536
18222255PlaceboNasal sprays
13221152BB536
17223253PlaceboEye drops
 6＊111021BB536
＊p＜0.05, diference in total counts vs placebo groups, Fisher’ sexact test.
day and the day following exposures (Fig. 3). No sig-
nificant differences were apparent in the numbers of
subjects taking these medications; however, signifi-
cantly lower prevalence was found for the total counts
of the number of days for oral medication and eye
drop usage in the BB536 group when compared to
the placebo group (Table 3). AUC analysis indicated
significantly lower scores for eye drops (p = 0.047)
and the total medications used (p = 0.041) along with
a tendency towards a decrease in oral medication use
(p = 0.093) (Table 2).
BLOOD PARAMETERS
No marked changes were found for the total and JCP-
specific IgE levels between the first and the second
blood samplings as well as between the BB536 and
placebo groups.
DISCUSSION
This double-blind, placebo-controlled, crossover
study indicated that as compared to placebo, BB536
intake was associated with a significant improvement
of ocular symptoms during pollen exposures, and an
improvement of both the scores for the disruption of
normal activities and the need for medication use af-
ter JCP exposure in patients with JCP allergy. These
results confirm the effect of BB536 intake in relieving
subjective symptoms.
The efficacy of probiotics in preventing allergic de-
velopment and treating already established allergic
diseases remains controversial.11 Many reasons
could account for the different outcomes in the vari-
ous clinical trials and include variation of the dose
and intake period, differences in the type and the se-
verity of the symptoms involved, and most impor-
tantly, differences in the species and the strains of the
probiotics used. In order to overcome the problems
associated with field-based studies, such as differ-
ences in pollen amounts and symptom severities that
are found within or between seasons, we assessed
the efficacy of BB536 intake on the output of symp-
toms under controlled exposures to JCP in an EEU
during the non-pollen season in a two-way crossover
design. Our results suggest that this method is useful
for comparative study of different agents in allergy
disease treatment.
Allergic disorders, such as allergic asthma, rhinitis
and atopic dermatitis, are characterized by an imme-
diate hypersensitivity reaction followed by a delayed
inflammatory reaction (late-phase response). Type I
allergy is characterized by a Th2-skewed immune re-
sponse upon exposure to allergens, which causes the
synthesis of allergen-specific IgE. The immediate re-
actions, which included responses such as sneezing,
rhinorrhea, eye symptoms, etc, which are observed
with early contact with the sensitizing allergen, are
consecutive with the IgE-dependent activation of the
mast cells that subsequently release stored mediators
that are preformed in the granules, such as histamine
or tumor necrosis factor-α, or are newly synthesized,
such as arachidonic acid metabolites prosta-
glandin.21,22 The late inflammatory reactions, which
included responses such as nasal blocking, etc, that
occurs several hours after contact with the allergen
and which contributes to cell damage are character-
ized by tissue infiltration by eosinophils and T lym-
phocytes (mainly CD4+ T helper 2 cells).21,22 The in-
filtration is tightly controlled by chemokines such as
TARC and MDC (macrophage-derived chemokine)
that selectively attract Th2 memory T cells.21
The reason why BB536 demonstrates benefits only
on ocular symptoms and not on other symptoms dur-
ing exposures is unclear, however, several explana-
tions can be proposed. First, differences existed for
exposure patterns between EEU and the pollen sea-
son. In the EEU, it was designed to be a concen-
trated, heavy exposure for a few hours. Within such a
short time, immunological changes with possible re-
lation to symptom development would not be ex-
pected. Under natural conditions, however, the expo-
sure is successive for several months. There is also a
preseason with a mild pollen scattering before the on-
set of pollen season. Such an induction phase as well
as the successive exposure would affect the immu-
nological system. These differences might have influ-
enced the outcomes of BB536 intake. Second, there
Xiao J et al.
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were differences in responses for each symptom in
the EEU. Nasal symptoms responded abruptly upon
exposure in the EEU, especially with regard to sneez-
ing and rhinorrhea, which increased to maximum
scores within 30 to 60 minutes. However, eye symp-
toms showed gradual responses upon exposure. Fur-
thermore, our results and a previous report indicated
that EEU exposure tended to cause rapid response of
nasal blocking, and delayed symptoms occurred sev-
eral hours after exposure to allergens under natural
exposure.14 The unusual responses of nasal symp-
toms might have limited the effects of BB536 intake.
Thirdly, another limitation of BB536 efficiency may
be related to the EEU exposure. The effect of probiot-
ics in the treatment of allergy diseases has been sug-
gested to occur via a modulation of the immune re-
sponses.23-25 BB536 was found to significantly sup-
press the increase of plasma TARC in a trial carried
out in the 2005 JCP season.13 In contrast to other
treatments such as histamine release inhibitors or an-
tihistamines, the effects of probiotics are expected to
be mild and have a lag in the effect on expression.
For these reasons, in the present study BB536 was
administrated for 4 weeks before pollen exposure;
however, the short time (4 hours) combined with the
heavy amounts of pollen used might have surpassed
the efficiency limit of BB536 in alleviating all symp-
toms during pollen exposures.
Interestingly, we found that some of the delayed
symptoms and the medication use after exposures
were reduced by BB536 intake. Similarly, we found
that BB536 intake alleviated the subjective symptoms
and increased the number of JCPsis subjects that did
not have to take their prescribed pollinosis medicines
during the heavy 2005 pollen season.13 Eye drops, na-
sal sprays or oral pollinosis medications are usually
prescribed for practical precaution, self-care, or medi-
cal treatment. Since possible adverse effects can be a
problem with such treatments, it would be desirable
if the use of these medications could be decreased,
and therefore, probiotic use is a worthwhile goal to
pursue.
In conclusion, the present study confirms the bene-
ficial impact of BB536 intake on JCP allergies that
have been reported in studies undertaken during pre-
vious pollen seasons. Additionally, other benefits
noted include the relief of subjective symptoms and a
concurrent reduction in medication use as compared
to the placebo response to allergen exposure.
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